By Manas Mishra and Michael Erman (Reuters) -Pfizer Inc maintained sales forecasts for its pandemic products on Tuesday after a series of hikes to revenue projections for its COVID-19 vaccine last year, in a sign that dizzying growth has slowed. Several countries have eased pandemic restrictions, relaxing rules on masking and quarantines, even as cases rise in some regions. The company said it expects $22 billion in sales from its COVID treatment Paxlovid this year, compared with analysts’ average expectation of $26.1 billion, according to Refinitiv. Pfizer had previously said its $22 billion …